<DOC>
	<DOC>NCT00089570</DOC>
	<brief_summary>The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.</brief_summary>
	<brief_title>Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Chronic, or acute liver disease Rapidly progressive reduction in renal function, e.g. doubling of serum creatinine to &gt;2.5 mg/dL in less than two weeks. No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion Proteinuria &lt;500 mg per day No evidence of granular casts in urinalysis or ultrasonographic evidence of obstructive uropathy or parenchymal renal disease Ongoing shock Uncontrolled bacterial infection Current significant fluid losses Current or recent treatment with nephrotoxic drugs (e.g. NSAIDs or aminoglycosides within 4 weeks) Acute liver disease due to factors known to be also directly nephrotoxic (e.g. acetaminophen overdose) Confirmed pregnancy Severe cardiovascular disease Evidence of intrinsic or parenchymal renal disease (e.g. acute tubular necrosis) Participation in other clinical studies within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>hepatorenal syndrome</keyword>
	<keyword>terlipressin</keyword>
</DOC>